Note: Articles may be assigned to more than one subject area, as a result the sum of the subject research outputs may not equal the overall research outputs. Actionable insights into research ...

SAN DIEGO - February 24, 2009 - Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced positive results from the second of two double-blind pivotal Phase 3 trials assessing the safety and ...

STATEN ISLAND, N.Y., Dec. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule ...

Saint-Herblain (France), June 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical trials of Lyme disease ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today ...

BOSTON, April 15, 2026 (GLOBE NEWSWIRE)-- Elion Therapeutics, a biotechnology company dedicated to transforming the treatment of life-threatening fungal infections, today announced the initiation of ...

Crestone, Inc. (“Crestone”) today announced recent publication in the leading infectious disease journal, The Lancet Infectious Diseases, of positive results from a Phase 2 clinical trial evaluating ...

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data ...

Memo Therapeutics is pressing ahead with its kidney transplant infection drug, advancing it to Phase III trials, despite falling short of its primary endpoint in a Phase II trial. The SAFE KIDNEY II ...

In a recent article published in the bioRxiv* preprint server, researchers examined immune reflexes towards severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among pregnant women.